Literature DB >> 22721856

Drug delivery strategies for the treatment of malignant gliomas.

Daniela Allhenn1, Maryam Alsadat Shetab Boushehri, Alf Lamprecht.   

Abstract

As primary brain tumors, malignant gliomas are known to be one of the most insidious types of brain cancer afflicting the humans. The current standard strategy for the treatment of malignant gliomas includes the surgical resection of the tumor when possible, followed by a combination of radiotherapy and/or a certain chemotherapeutic protocol. However, due to the short mean survival, frequent recurrences, and poor prognosis associated with the tumors, new therapeutic strategies are investigated consecutively. These novel drug delivery approaches can be subdivided as systemic and local drug administration. This review focuses on localized drug delivery strategies for the treatment of malignant gliomas, including the injections, infusions, trans-nasal delivery systems, convection enhanced delivery (CED) systems, and various types of polymeric implants. Furthermore, systemic strategies to increase the drug penetration into the brain, such as temporary disruption of the blood brain barrier (BBB), chemical modification of the available therapeutic substances, and utilization of endogenous transport systems will be briefly discussed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721856     DOI: 10.1016/j.ijpharm.2012.06.025

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  34 in total

1.  Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.

Authors:  M H Lopes; T G Santos; B R Rodrigues; N Queiroz-Hazarbassanov; I W Cunha; A P Wasilewska-Sampaio; B Costa-Silva; F A Marchi; L F Bleggi-Torres; P I Sanematsu; S H Suzuki; S M Oba-Shinjo; S K N Marie; E Toulmin; A F Hill; V R Martins
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

2.  Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Authors:  Samuel A Jensen; Emily S Day; Caroline H Ko; Lisa A Hurley; Janina P Luciano; Fotini M Kouri; Timothy J Merkel; Andrea J Luthi; Pinal C Patel; Joshua I Cutler; Weston L Daniel; Alexander W Scott; Matthew W Rotz; Thomas J Meade; David A Giljohann; Chad A Mirkin; Alexander H Stegh
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

3.  MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.

Authors:  Xiaoli Liu; Achuthamangalam B Madhankumar; Patti A Miller; Kari A Duck; Susan Hafenstein; Elias Rizk; Becky Slagle-Webb; Jonas M Sheehan; James R Connor; Qing X Yang
Journal:  Neuro Oncol       Date:  2015-10-31       Impact factor: 12.300

Review 4.  Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma.

Authors:  Andrew W Smith; Minesh P Mehta; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2016-04-23       Impact factor: 4.130

Review 5.  Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.

Authors:  Erica C Kaye; Justin N Baker; Alberto Broniscer
Journal:  CNS Oncol       Date:  2014-11

Review 6.  Targeted delivery of nano-therapeutics for major disorders of the central nervous system.

Authors:  Huile Gao; Zhiqing Pang; Xinguo Jiang
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

7.  Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma.

Authors:  Brent D Weinberg; Lauren Boreta; Steve Braunstein; Soonmee Cha
Journal:  J Neurooncol       Date:  2018-03-15       Impact factor: 4.130

Review 8.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 9.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

10.  Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants.

Authors:  Ana Gabriela Reis Solano; Adriana de Fátima Pereira; Flavia Carmo Horta Pinto; Letícia Gonçalves Resende Ferreira; Leandro Augusto de Oliveira Barbosa; Silvia Ligório Fialho; Patrícia Santiago de Oliveira Patricio; Armando da Silva Cunha; Gisele Rodrigues da Silva; Gérson Antônio Pianetti
Journal:  AAPS PharmSciTech       Date:  2013-05-11       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.